SIRT4抗体

+ +

•  

   

     Black line: Control Antigen (100 ng); Purple line: Antigen(10ng); Blue line: Antigen (50 ng); Red line: Antigen (100 ng);    

  
  

•  

   

     Immunofluorescence analysis of HeLa cells using SIRT4 mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor- 555 phalloidin. Secondary antibody from Fisher (Cat#: 35503)    

  
  

•  

   

     Flow cytometric analysis of HeLa cells using SIRT4 mouse mAb (green) and negative control (red).    

  
  

SIRT4 (Sirtuin 4) is a member of the sirtuin family of NAD+-dependent deacylases, primarily localized in mitochondria. It plays a critical role in regulating metabolic pathways, including fatty acid oxidation, amino acid metabolism, and insulin secretion. Unlike other sirtuins (e.g., SIRT1 or SIRT3), SIRT4 exhibits weak deacetylase activity but primarily functions as an ADP-ribosyltransferase, modulating enzyme activities to maintain metabolic homeostasis. Its involvement in suppressing tumor growth, promoting DNA repair, and influencing cellular stress responses has linked SIRT4 to aging, cancer, and metabolic disorders like diabetes.

SIRT4 antibodies are essential tools for detecting and quantifying SIRT4 protein levels in research. They are widely used in techniques such as Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and ELISA to study SIRT4 expression patterns across tissues, its subcellular localization, and interactions with metabolic enzymes. High-quality SIRT4 antibodies are validated for specificity, often using knockout (KO) models to confirm minimal cross-reactivity with other sirtuins. These antibodies enable investigations into SIRT4's role in mitochondrial dysfunction, cancer progression (e.g., as a tumor suppressor in certain cancers), and metabolic syndrome. Commercial SIRT4 antibodies are typically raised against conserved epitopes, available as monoclonal or polyclonal variants, and require optimization for experimental conditions. Recent studies leveraging these reagents highlight SIRT4’s therapeutic potential, driving demand for reliable antibodies in both basic and translational research.